ProQR Therapeutics (PRQR) Projected to Post Quarterly Earnings on Thursday

ProQR Therapeutics (NASDAQ:PRQR) is anticipated to release its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.10) per share and revenue of $7.0520 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Friday, November 7, 2025 at 9:30 AM ET.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). ProQR Therapeutics had a negative return on equity of 61.25% and a negative net margin of 238.52%.The business had revenue of $4.33 million during the quarter, compared to analysts’ expectations of $5.01 million. On average, analysts expect ProQR Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ProQR Therapeutics Price Performance

Shares of ProQR Therapeutics stock opened at $2.65 on Thursday. The stock has a market cap of $278.81 million, a price-to-earnings ratio of -5.76 and a beta of 0.23. The firm’s 50-day moving average is $2.37 and its two-hundred day moving average is $2.05. ProQR Therapeutics has a 1 year low of $1.07 and a 1 year high of $4.21.

Institutional Investors Weigh In On ProQR Therapeutics

Several institutional investors have recently bought and sold shares of PRQR. Osaic Holdings Inc. boosted its stake in ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 4,500 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of ProQR Therapeutics by 699.3% during the 1st quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 79,720 shares during the last quarter. Bank of America Corp DE boosted its position in shares of ProQR Therapeutics by 25.7% in the 2nd quarter. Bank of America Corp DE now owns 119,198 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 24,347 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its position in shares of ProQR Therapeutics by 28.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 121,494 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 26,893 shares in the last quarter. 32.65% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Evercore ISI reiterated an “outperform” rating on shares of ProQR Therapeutics in a research note on Friday, July 11th. Chardan Capital restated a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a report on Friday, August 8th. Zacks Research downgraded ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Wednesday, October 8th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, ProQR Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.14.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).